A Clinical Study to Compare Long-term Efficacy and Safety... | NCT00219154

Official Title

A Twenty Six-week, Randomized, Double-blind, Parallel Group, Multicenter, Active Controlled, Dose Titration Study to Evaluate the Efficacy and Safety of Aliskiren Compared to HCTZ With the Optional Addition of Amlodipine, Followed by a Second Twenty Six Weeks of Blinded Treatment, in Patients With Essential Hypertension

Status Module

Description Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Name	Type	Description	Arm Group Labels	Other Names
aliskiren	Drug

Outcomes Module

Measure	Description	Time Frame
Change from baseline in diastolic blood pressure after 26 weeks

Secondary Outcomes

Measure	Description	Time Frame
Change from baseline systolic blood pressure after 26 weeks
Mean sitting diastolic blood pressure < 90 mmHg or a reduction of > 10 mmHg after 26 weeks
Achieve blood pressure of < 140/90 mmHg after 26 weeks

Eligibility Module

Contacts/Locations Module

Name	Affiliation	Role
Novartis Pharmaceuticals	Novartis Pharmaceuticals	Study Director

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
19139391	Derived	Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, Maboudian M, Botha J, van Ingen H. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation. 2009 Jan 27;119(3):417-25. doi: 10.1161/CIRCULATIONAHA.107.750745. Epub 2009 Jan 12.

Derived Section

Miscellaneous Info Module

Submission Tracking

No data available

No data is available for this block.

Condition Browse Module

Intervention Browse Module

Facility	Status	City	State	ZIP	Country	Contacts
		Investigative Centers			Germany
Novartis Pharmaceuticals

ID	Term
D014652	Vascular Diseases
D002318	Cardiovascular Diseases